Sutro Biopharma (STRO) News Today $2.01 +0.16 (+8.65%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $11.13 Consensus Target Price from BrokeragesShares of Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight analysts that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating on tJanuary 20 at 1:36 AM | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesSutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and seven have issued a buy recJanuary 17 at 2:54 AM | marketbeat.comSutro Biopharma (STRO) Gets a Buy from Bank of America SecuritiesJanuary 17 at 12:03 AM | markets.businessinsider.comSutro Biopharma: Strategic Partnerships and Promising Pipeline Drive Buy RatingJanuary 17 at 12:03 AM | markets.businessinsider.comSutro Biopharma, Inc. (NASDAQ:STRO) Sees Large Growth in Short InterestSutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) was the target of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 3,150,000 shares, an increase of 28.0% from the December 15th total of 2,460,000 shares. Based on an average trading volume of 925,500 shares, the short-interest ratio is presently 3.4 days.January 16, 2025 | marketbeat.comAnalyzing Sorrento Therapeutics (OTCMKTS:SRNEQ) and Sutro Biopharma (NASDAQ:STRO)January 11, 2025 | americanbankingnews.comSutro Biopharma, Boehringer announce application of Sutro’s technologyJanuary 7, 2025 | markets.businessinsider.comSutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | globenewswire.comSutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scaleJanuary 7, 2025 | markets.businessinsider.comSutro Biopharma: I Don't Buy That Their Pipeline Is WorthlessJanuary 2, 2025 | seekingalpha.comShort Interest in Sutro Biopharma, Inc. (NASDAQ:STRO) Expands By 19.4%Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) was the recipient of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 2,460,000 shares, a growth of 19.4% from the November 30th total of 2,060,000 shares. Based on an average daily volume of 900,500 shares, the days-to-cover ratio is currently 2.7 days.December 29, 2024 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of "Moderate Buy" from AnalystsSutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and seven have assigned aDecember 23, 2024 | marketbeat.comSutro Biopharma, Inc.'s (NASDAQ:STRO) latest 24% decline adds to one-year losses, institutional investors may consider drastic measuresDecember 20, 2024 | finance.yahoo.comPromising Developments in Sutro Biopharma’s Luvelta Drive Buy RatingDecember 12, 2024 | markets.businessinsider.comSutro Biopharma price target lowered to $4 from $5 at Wells FargoDecember 12, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Sutro Biopharma (STRO)December 11, 2024 | markets.businessinsider.comStrong Buy Rating for Sutro Biopharma Amid Promising Trial Results and Strategic Financial PositionDecember 11, 2024 | markets.businessinsider.comPoint72 Asset Management L.P. Lowers Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO)Point72 Asset Management L.P. reduced its stake in shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 32.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,997,453 sharesDecember 8, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Sells 228,443 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO)Jacobs Levy Equity Management Inc. reduced its position in shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 21.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 821,746 shares of the cDecember 8, 2024 | marketbeat.comSutro Biopharma (STRO) Receives a Buy from Piper SandlerDecember 5, 2024 | markets.businessinsider.comBank of Montreal Can Invests $2.85 Million in Sutro Biopharma, Inc. (NASDAQ:STRO)Bank of Montreal Can acquired a new stake in Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 814,955 shares of the company's stock, valued at approximaDecember 5, 2024 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Short Interest UpdateSutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) was the target of a large decrease in short interest in November. As of November 15th, there was short interest totalling 1,790,000 shares, a decrease of 25.4% from the October 31st total of 2,400,000 shares. Based on an average trading volume of 647,400 shares, the days-to-cover ratio is currently 2.8 days.November 29, 2024 | marketbeat.comSuvretta Capital Management LLC Sells 521,195 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO)Suvretta Capital Management LLC decreased its holdings in Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 6.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,187,495 shares of the company's stock after selling 521,195 shares during theNovember 29, 2024 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of "Buy" by BrokeragesSutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) has been given a consensus rating of "Buy" by the seven brokerages that are presently covering the stock, Marketbeat reports. Seven analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages thatNovember 28, 2024 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of "Buy" from BrokeragesSutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) has earned an average recommendation of "Buy" from the seven ratings firms that are covering the stock, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 12 month price target amongNovember 28, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Acquires New Shares in Sutro Biopharma, Inc. (NASDAQ:STRO)Connor Clark & Lunn Investment Management Ltd. bought a new position in Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 437,051 shares of the company's stock, valued at approNovember 27, 2024 | marketbeat.comBrokers Set Expectations for Sutro Biopharma FY2024 EarningsSutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Investment analysts at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for shares of Sutro Biopharma in a research report issued on Monday, November 18th. HC Wainwright analyst A. Fein now anticipates that the company will eNovember 20, 2024 | marketbeat.comAnalysts Set Expectations for Sutro Biopharma Q2 EarningsSutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Research analysts at HC Wainwright issued their Q2 2025 EPS estimates for shares of Sutro Biopharma in a research note issued on Monday, November 18th. HC Wainwright analyst A. Fein expects that the company will post earnings of ($0.87) per sharNovember 19, 2024 | marketbeat.comSutro Biopharma’s Innovative ADC Technology and Strategic Partnerships Signal Strong Growth PotentialNovember 18, 2024 | markets.businessinsider.comSutro Biopharma's (STRO) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $12.00 price target on shares of Sutro Biopharma in a research note on Monday.November 18, 2024 | marketbeat.comSutro Biopharma FY2024 EPS Forecast Increased by WedbushSutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Analysts at Wedbush boosted their FY2024 earnings per share estimates for Sutro Biopharma in a research report issued on Wednesday, November 13th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($2.93) per shaNovember 18, 2024 | marketbeat.comSutro Biopharma, Inc.: Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business HighlightsNovember 15, 2024 | finanznachrichten.deSutro Biopharma: Hold Rating Amidst Uncertain Catalysts and Funding ConcernsNovember 15, 2024 | markets.businessinsider.comSutro Biopharma (STRO) Receives a Buy from Truist FinancialNovember 15, 2024 | markets.businessinsider.comSutro Biopharma’s Promising Market Expansion and Financial Stability Justify ‘Buy’ RatingNovember 15, 2024 | markets.businessinsider.comSutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Baillie Gifford & Co.Baillie Gifford & Co. lowered its holdings in Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 17.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,519,341 shares of the company's stock after selling 329,410 shares during the quarter.November 14, 2024 | marketbeat.comSutro Biopharma Reports Third Quarter 2024 Financial Results and Business HighlightsNovember 13, 2024 | globenewswire.comSutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC ConferenceNovember 4, 2024 | globenewswire.comSutro Biopharma initiates REFRaME-P1 trial of luvelta in AMLNovember 2, 2024 | markets.businessinsider.comSutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AMLNovember 1, 2024 | globenewswire.comSutro Biopharma (NASDAQ:STRO) Stock Quotes, Forecast and News SummaryOctober 29, 2024 | benzinga.comSutro Biopharma (NASDAQ:STRO) shareholders have endured a 80% loss from investing in the stock three years agoOctober 21, 2024 | finance.yahoo.comSutro Elementary parents decry 'chaos' at SF Unified over school closuresOctober 18, 2024 | msn.comSutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Cubist Systematic Strategies LLCCubist Systematic Strategies LLC lessened its position in shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 91.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 16,463 shares of the company's stocOctober 17, 2024 | marketbeat.comAQR Capital Management LLC Boosts Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO)AQR Capital Management LLC lifted its position in shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 691.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 283,516 shares of the company's stock after acquiring an additional 247,694 shares duringOctober 13, 2024 | marketbeat.comSutro Biopharma: Poised to Become an ADC Powerhouse with Innovative XpressCF(+) PlatformOctober 12, 2024 | markets.businessinsider.comSutro Biopharma’s Promising ADC Innovations and Strategic Collaborations Justify a Buy RatingOctober 12, 2024 | markets.businessinsider.comTruist Financial Issues a Buy Rating on Sutro Biopharma (STRO)October 11, 2024 | markets.businessinsider.comSutro Biopharma (STRO) Gets a Buy from WedbushOctober 11, 2024 | markets.businessinsider.comSutro Biopharma's (STRO) "Overweight" Rating Reaffirmed at Piper SandlerPiper Sandler reissued an "overweight" rating and set a $11.00 price objective on shares of Sutro Biopharma in a research report on Friday.October 11, 2024 | marketbeat.com Get Sutro Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Email Address STRO Media Mentions By Week STRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. STRO News Sentiment▼0.580.44▲Average Medical News Sentiment STRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. STRO Articles This Week▼52▲STRO Articles Average Week Get Sutro Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Bicara Therapeutics News Immatics News Immunome News Ginkgo Bioworks News LENZ Therapeutics News Arbutus Biopharma News Tectonic Therapeutic News Cullinan Therapeutics News Dianthus Therapeutics News Autolus Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:STRO) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sutro Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
